AC Immune to Host Key Opinion Leader Webinar on Alpha-Synuclein as a Target in Neurodegenerative Diseases
21 mars 2022 07h30 HE
|
AC Immune SA
LAUSANNE, Switzerland, March 21, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
AC Immune Reports First Live Images of Alpha-Synuclein in Human Brain with New PET Tracer for Neurodegenerative Disease at AD/PDTM Conference
16 mars 2022 07h41 HE
|
AC Immune SA
ACI-12589 distinguished multiple system atrophy (MSA) from other a-synucleinopathies and healthy volunteers A-syn PET tracers may be developed to diagnose a-synuclein pathologies, including...
AC Immune to Present at the AD/PD™ 2022 New Clinical and Preclinical Data for Alpha-Synuclein, Abeta and TDP-43 Programs
28 févr. 2022 07h30 HE
|
AC Immune SA
Five presentations at the International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM) AC Immune’s Chief Medical Officer to participate in expert forum on translational drug discovery...
AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort
15 févr. 2022 07h30 HE
|
AC Immune SA
Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment ACI-35.030 continues to be well tolerated with no clinically relevant safety concerns observed...
AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease
04 févr. 2022 07h30 HE
|
AC Immune SA
Results differentiate ACI-24 as potential best-in-class Abeta vaccine in development Strong response against neurotoxic pyroGlu-Abeta variants observed in non-human primates Data further support...
AC Immune to Present at the SVB Leerink 11th Annual Global Healthcare Conference
02 févr. 2022 08h58 HE
|
AC Immune SA
LAUSANNE, Switzerland, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today...
AC Immune Awarded Two Michael J. Fox Foundation Grants to Advance Small Molecule Parkinson’s Disease Programs
15 déc. 2021 07h49 HE
|
AC Immune SA
Funding to accelerate the development of first-in-class brain penetrant small molecules to inhibit a-syn aggregation and NLRP3 inflammasome activation in Parkinson’s disease (PD) Programs targeting...
AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer’s Vaccine Generates a Potent Immune Response
12 nov. 2021 08h21 HE
|
AC Immune SA
Observed strong induction of antibodies specific for pathological forms of Tau with ACI-35.030 treatment New data presented at 14th CTAD conference support ACI-35.030’s advancement into late-stage...
AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to-Moderate Alzheimer’s Disease
10 nov. 2021 11h20 HE
|
AC Immune SA
Analysis of the broader mITT population is consistent with the previously reported success in meeting one of the two co-primary endpoints (ADAS-Cog11) with statistically significant reduction in the...
AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update
08 nov. 2021 07h00 HE
|
AC Immune SA
Announced the first positive cognitive results for a Tau-targeting monoclonal antibody in mild-to-moderate Alzheimer’s disease Closed its strategic acquisition of an industry-leading Parkinson’s...